Novel approaches
to vascular therapy

Angios is a biotechnology company, specializing in vascular research to improve
patients' lives all over the world. We are based in Austria, the US and Canada.

The need

Blood vessels are the lifelines of our body. Diseases affecting their functionality remain one of the big unresolved global health problems. Especially diabetic patients suffer from a multitude of vascular complications that can cause blindness, non-healing wounds and kidney failure.

The solution

Angios strives to develop new treatments for these challenging diabetic vascular diseases by pursuing pre-identified targets for diabetic retinopathy and by leveraging the vascular organoid model developed in the laboratories of our founders.

David Hoffmann, PhD

CSO
Meet David

Gregor Wick

CEO
Meet Gregor

Josef Penninger, MD

Chairman of the Scientific Advisory Board
Meet Josef

Maria Dumitrascuta

Scientist
Vita

Elisabeth Pfeiffenberger

Scientist
Vita

Nicole Przysiecki

Labmanager
Vita

Florian Regensberger

Research administration
Vita

Prof. Josef Penninger, MD

Chairman
Vita

Ulrich Granzer, PhD

Granzer Regulatory Consulting & Services
Vita

Carl Hansen, PhD

CEO, abCellera Vancouver
Vita

Prof. Christine Mummery, PhD

Professor of Developmental Biology, Leiden
Vita

Prof. Herbert Tilg, PhD

Professor of internal medicine, Medical University Innsbruck
Vita

Reiner Wimmer, PhD

Scientist, Pharma Reasearch and Early Development, Roche Basel
Vita

The people behind Angios

We are a multi-disciplinary team of scientists that is united by a common goal – to advance our science into therapies. Our team members have different expertise and scientific background, which fosters a highly collaborative work environment. As a new biotech start-up, our company culture is built on teamwork, communication, fun and a passion for science.